ERBB2 and breast carcinoma: HR‐positive/HER2‐negative breast cancer patients with PIK3CA mutation whose previous line of therapy was CDK4/6 inhibitor combined with endocrine therapy and who exhibited disease progression with systemic chemotherapy or endocrine therapy (n = 336)